The purpose of this study is to collect data on patients with severe uveitis that have
required re-implantation of the sustained-release fluocinolone drug delivery device due to
depletion of study drug in their previous implanted device.
Purpose: To collect medical information on a sustained release drug delivery system that
delivers the corticosteroid, fluocinolone acetonide, directly into the vitreous cavity of
the eye. This system has the potential to maintain therapeutic drug levels in the eye while
reducing systemic exposure to the drug to negligible levels. RetisertTM is the trade name
for the intravitreal fluocinolone acetonide implant.
Hypothesis: The RetisertTM will be a safe and effective method to manage patients with
- Non-infectious intermediate, posterior or panuveitis
- Previous placement of fluocinolone acetonide implant with initial uveitis quiescence
and subsequent recurrence of inflammation once implant depleted of drug
- Infectious uveitis